Rosalind Advisors Inc. Purchases Shares of 2,654,944 Savara Inc (NASDAQ:SVRA)

Rosalind Advisors Inc. bought a new position in Savara Inc (NASDAQ:SVRA - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 2,654,944 shares of the company's stock, valued at approximately $8,151,000. Savara comprises approximately 4.0% of Rosalind Advisors Inc.'s portfolio, making the stock its 9th biggest position. Rosalind Advisors Inc. owned about 1.55% of Savara as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. The Manufacturers Life Insurance Company increased its stake in Savara by 9.0% during the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company's stock worth $191,000 after acquiring an additional 3,706 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Savara by 14.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock worth $112,000 after purchasing an additional 4,732 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Savara by 5.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company's stock worth $533,000 after purchasing an additional 6,141 shares during the last quarter. SG Americas Securities LLC raised its holdings in Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock valued at $158,000 after buying an additional 6,330 shares during the period. Finally, Rhumbline Advisers lifted its position in Savara by 6.8% in the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company's stock valued at $434,000 after buying an additional 9,041 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

SVRA has been the topic of a number of research analyst reports. Wells Fargo & Company initiated coverage on shares of Savara in a research note on Friday, December 20th. They issued an "overweight" rating and a $8.00 price target on the stock. JMP Securities reissued a "market outperform" rating and issued a $9.00 target price on shares of Savara in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Savara has an average rating of "Moderate Buy" and a consensus target price of $8.83.

Savara Stock Down 2.5 %

Shares of SVRA stock traded down $0.07 during trading on Wednesday, reaching $2.70. The company's stock had a trading volume of 992,649 shares, compared to its average volume of 1,283,197. The company has a market capitalization of $463.37 million, a price-to-earnings ratio of -6.28 and a beta of 0.60. Savara Inc has a 1-year low of $2.26 and a 1-year high of $5.34. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock's 50-day moving average price is $2.73 and its 200 day moving average price is $3.28.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.